Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HPD | P32754 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | LITAF | Q99732 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.31 |
| ▸ | EEF2K | O00418 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946448 | 0.86 | ALDH1A1 (0.45) | ALDH1A1GAAKDM4EMAPTGFER | |
| SCHEMBL2329963 | 0.79 | ALDH1A1 (0.47) | ALDH1A1GAAKDM4EMAPTGFER | |
| SCHEMBL1546099 | 0.77 | ALDH1A1 (0.63) | ALDH1A1GAAKDM4EMAPTGFER | |
| SCHEMBL17582653 | 0.76 | ALDH1A1 (0.66) | ALDH1A1GAAKDM4EMAPTGFER | |
| SCHEMBL25086824 | 0.75 | P2RX3 (0.40) | ALDH1A1KDM4EGSK3AGSK3BHPD | |
| SCHEMBL20942675 | 0.73 | POLB (0.46) | ALDH1A1KDM4EMAPTGSK3AGSK3B | |
| SCHEMBL239409 | 0.73 | ALDH1A1 (0.45) | ALDH1A1GAAKDM4EMAPTGFER | |
| SCHEMBL19993561 | 0.72 | GSK3B (0.47) | ALDH1A1GAAKDM4EMAPTGFER | |
| SCHEMBL1948066 | 0.70 | ADORA2B (0.46) | ALDH1A1GAAKDM4EMAPTGFER | |
| SCHEMBL5552020 | 0.69 | LMNA (0.47) | GSK3AGSK3BHPDTNFLITAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304070-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050101778-A1 | A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101778-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 505/4885GAA 2205/4885KDM4E 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.